ClinicalTrials.gg
CompletedNCT05507580Flex-UpUpdated Jul 29, 2025Results posted

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 4 interventional study of Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 106 sites in 18 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
8th of 17
461 · median 272
Started
2023
the only one that year
Phase 4
2 of 17
1 open now
Registered
10th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed.

Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide.

The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis (AD)
  • Upadacitinib
  • RINVOQ
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and participant meets Hanifin and Rajka criteria.
  • Eczema Area and Severity Index (EASI) score >= 16, vIGA-AD score >= 3 and >= 10% Body Surface Area (BSA) of AD involvement at the Baseline Visit.
  • Baseline weekly average of daily Worst Pruritus NRS >= 4.
  • Candidate for systemic treatment defined as prior use of systemic treatment for AD, OR previous inadequate response to TCS, TCI or PDE-4 inhibitors, OR for whom topical treatments are otherwise medically inadvisable.

Exclusion criteria

Exclusion Criteria:

  • Participants with current or past history of infection including:

    • Two or more episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;
    • One or more episodes of disseminated herpes simplex (including eczema herpeticum);
    • (HIV) infection defined as confirmed positive anti-HIV antibody (HIV Ab) test;
    • Active tuberculosis (TB) or meet TB exclusionary parameters (protocol specified requirements for TB testing);
    • Japan only: Positive result of beta-D-glucan (screening for Pneumocystis jirovecii infection) or two consecutive indeterminate results of beta-D-glucan during the Screening Period;
    • Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit;
    • Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study;
    • COVID-19 infection: In participants who tested positive for COVID, at least 5 days must have passed since a COVID-19 positive test result for study entry of asymptomatic participants. Participants with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Participants may be rescreened if judged to be in good general health, as determined by the investigator based upon the medical history and physical examination.
  • Evidence of virus (HBV) or virus (HCV).
  • Any of the following medical diseases or disorders:

    • Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery;
    • History of an organ transplant which requires continued ;
    • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class;
    • History of gastrointestinal perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for gastrointestinal perforation per investigator judgment;
    • Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; participants with a history of gastric banding/segmentation are not excluded;
    • History of except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
461 participants (actual)

Study arms

  • Experimental
    UPA 15 mg Double-Blind Treatment Period

    Participants received 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Double-Blind Treatment Period.

    Drug: Upadacitinib

  • Experimental
    UPA 30 mg Double-Blind Treatment Period

    Participants received 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Double-Blind Treatment Period.

    Drug: Upadacitinib

  • Experimental
    UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period

    At Week 12 in the Double-Blind Treatment Period, participants receiving 15 mg upadacitinib orally once daily (QD) achieving a ≥ 90% reduction in the Eczema Area and Severity Index (EASI) (≥ EASI 90) were allocated to receive 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.

    Drug: Upadacitinib

  • Experimental
    UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period

    At Week 12 in the Double-Blind Treatment Period, participants receiving 15 mg upadacitinib orally once daily (QD) achieving a \< 90% reduction in the Eczema Area and Severity Index (EASI) (\< EASI 90) were allocated to receive 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.

    Drug: Upadacitinib

  • Experimental
    UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period

    At Week 12 in the Double-Blind Treatment Period, participants receiving 30 mg upadacitinib orally once daily (QD) achieving a ≥ 90% reduction in the Eczema Area and Severity Index (EASI) (≥ EASI 90) were allocated to receive 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.

    Drug: Upadacitinib

  • Experimental
    UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period

    At Week 12 in the Double-Blind Treatment Period, participants receiving 30 mg upadacitinib orally once daily (QD) achieving a \< 90% reduction in the Eczema Area and Severity Index (EASI) (\< EASI 90) were allocated to receive 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.

    Drug: Upadacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 24

  2. Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 24

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 24

  3. Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 12

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 12

  4. Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 12

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 12

  5. Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 12

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

    Time frame: Baseline and Week 12

  6. Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 12

  7. Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline

    The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 24

  8. Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 12

    vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).

    Time frame: At Week 12

  9. Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 24

    vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).

    Time frame: At Week 24

  10. Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥4

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 12

  11. Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥4

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 24

  12. Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >1

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 12

  13. Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >1

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 24

  14. Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥4

    DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

    Time frame: Baseline and Week 12

  15. Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥4

    DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

    Time frame: Baseline and Week 24

  16. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >1

    DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

    Time frame: Baseline and Week 12

  17. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >1

    DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

    Time frame: Baseline and Week 24

07

Results

Posted Jul 29, 2025

Participant flow

Double-Blind Treatment Period
Participant flow — Double-Blind Treatment Period
MilestoneUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Started2292320000
Completed2172260000
Not completed1260000
Withdrew: Lost to follow-up010000
Withdrew: Withdrawal by subject710000
Withdrew: Other, not specified540000
Single-Blind Treatment Period
Participant flow — Single-Blind Treatment Period
MilestoneUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Started007214413391
Completed007013212679
Not completed00212712
Withdrew: Lost to follow-up000021
Withdrew: Withdrawal by subject000526
Withdrew: Other, not specified002735

Outcome measures

PrimaryPercentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 2474.6 (64.5 to 84.8)48.1 (39.6 to 56.6)68.5 (60.5 to 76.4)29.3 (19.4 to 39.1)
SecondaryPercentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 2497.2 (93.3 to 100.0)69.2 (61.3 to 77.0)88.5 (83.0 to 94.0)52.4 (41.6 to 63.2)
SecondaryPercentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 24

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 24
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 2433.8 (22.8 to 44.8)7.5 (3.0 to 12.0)21.5 (14.5 to 28.6)3.7 (0.0 to 7.7)
SecondaryPercentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 12

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 12
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 1264.4 (58.1 to 70.7)79.3 (74.0 to 84.6)
SecondaryPercentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 12

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 12
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 1233.8 (27.6 to 40.0)59.9 (53.5 to 66.3)
SecondaryPercentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 12

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 12
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 127.7 (4.2 to 11.2)15.9 (11.1 to 20.6)
SecondaryPercentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline18.0 (12.5 to 23.6)32.5 (25.9 to 39.1)
SecondaryPercentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline

The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline38.5 (25.2 to 51.7)20.7 (12.0 to 29.5)35.0 (25.7 to 44.3)20.3 (10.1 to 30.6)
SecondaryPercentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 12

vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).

Time frame:
At Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 12
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 1229.7 (23.7 to 35.7)51.5 (45.0 to 58.0)
SecondaryPercentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 24

vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 24
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 2463.4 (52.2 to 74.6)40.6 (32.3 to 48.9)52.3 (43.7 to 60.9)29.3 (19.4 to 39.1)
SecondaryPercentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥4

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥4
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥453.3 (46.0 to 60.5)67.7 (61.1 to 74.3)
SecondaryPercentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥4

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥4
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥473.1 (61.0 to 85.1)57.3 (46.6 to 68.0)67.0 (57.8 to 76.2)60.0 (47.6 to 72.4)
SecondaryPercentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >1

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >1
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >127.3 (20.9 to 33.8)40.0 (33.1 to 46.9)
SecondaryPercentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >1

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >1
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >146.2 (32.6 to 59.7)32.5 (22.5 to 42.6)38.0 (28.5 to 47.5)28.3 (16.9 to 39.7)
SecondaryPercentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥4

DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥4
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥477.5 (71.9 to 83.1)88.9 (84.7 to 93.1)
SecondaryPercentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥4

DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥4
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥488.1 (80.3 to 95.8)82.2 (75.6 to 88.8)84.7 (78.3 to 91.0)74.0 (64.2 to 83.8)
SecondaryPercentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >1

DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >1
percentage of participantsUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >122.2 (16.7 to 27.8)36.5 (30.2 to 42.8)
SecondaryPercentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >1

DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >1
percentage of participantsUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >142.0 (30.4 to 53.7)24.0 (16.7 to 31.4)35.4 (27.1 to 43.8)15.2 (7.3 to 23.1)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 168 days for the Double-Blind Treatment Period groups and ranged from 168 to 169 days for the Single-Blind Treatment Period groups.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UPA 15 mg Double-Blind Treatment Period0/229 (0%)8/229 (3.5%)41/229 (17.9%)
UPA 30 mg Double-Blind Treatment Period0/232 (0%)0/232 (0%)67/232 (28.9%)
UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period0/72 (0%)1/72 (1.4%)17/72 (23.6%)
UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period0/144 (0%)1/144 (0.7%)38/144 (26.4%)
UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period0/133 (0%)1/133 (0.8%)39/133 (29.3%)
UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period0/91 (0%)0/91 (0%)33/91 (36.3%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/2290/2321/720/1440/1330/91
HUMERUS FRACTUREInjury, poisoning and procedural complications0/2290/2320/720/1441/1330/91
PYELONEPHRITISInfections and infestations0/2290/2320/721/1440/1330/91
CORONARY ARTERY DISEASECardiac disorders1/2290/2320/720/1440/1330/91
TOXIC NODULAR GOITREEndocrine disorders1/2290/2320/720/1440/1330/91
EPIDIDYMITISInfections and infestations1/2290/2320/720/1440/1330/91
ERYSIPELASInfections and infestations1/2290/2320/720/1440/1330/91
FALLInjury, poisoning and procedural complications1/2290/2320/720/1440/1330/91
HAND FRACTUREInjury, poisoning and procedural complications1/2290/2320/720/1440/1330/91
SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications1/2290/2320/720/1440/1330/91
Most frequent other events
Most frequent other events
EventUPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period
DERMATITIS ATOPICSkin and subcutaneous tissue disorders7/2299/2326/7223/14416/13315/91
ACNESkin and subcutaneous tissue disorders16/22932/2321/724/1448/1336/91
NASOPHARYNGITISInfections and infestations13/22921/2328/726/14410/1332/91
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/2299/2325/723/1444/1334/91
ORAL HERPESInfections and infestations4/2292/2320/720/1443/1335/91
ECZEMASkin and subcutaneous tissue disorders3/2292/2320/722/1441/1335/91

Baseline characteristics

ITT\_1 Population: all participants who were randomized in the Double-Blind Treatment Period

Age, Continuous
Age, Continuous(years)UPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodTotal
Mean34.4 ± 12.0632.7 ± 10.8333.5 ± 11.48
Sex: Female, Male
Sex: Female, Male(Participants)UPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodTotal
Female95110205
Male134122256
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)UPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodTotal
Hispanic or Latino10919
Not Hispanic or Latino219223442
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UPA 15 mg Double-Blind Treatment PeriodUPA 30 mg Double-Blind Treatment PeriodTotal
American Indian or Alaska Native101
Asian6766133
Native Hawaiian or Other Pacific Islander246
Black or African American235
White155158313
More than one race202
Unknown or Not Reported011
08

Study locations

106 sites
  • Momentum Clinical Research /ID# 254028
    Darlinghurst, New South Wales 2010, Australia
  • Premier Specialist /ID# 246150
    Kogarah, New South Wales 2217, Australia
  • Veracity Clinical Research /ID# 246154
    Woolloongabba, Queensland 4102, Australia
  • North Eastern Health Specialists /ID# 246153
    Campbelltown, South Australia 5074, Australia
  • Skin Health Institute Inc /ID# 246146
    Carlton, Victoria 3053, Australia
  • Cliniques Universitaires UCL Saint-Luc /ID# 245842
    Woluwe-Saint-Lambert, Brussels Capital 1200, Belgium
  • Grand Hôpital De Charleroi - Notre Dame /ID# 245837
    Charleroi, Hainaut 6000, Belgium
  • AZ Sint-Lucas /ID# 253708
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Dermatologie Maldegem /ID# 245840
    Maldegem, Oost-Vlaanderen 9990, Belgium
  • CHU de Liege /ID# 245839
    Liège, 4000, Belgium
  • UMHAT Alexandrovska EAD /ID# 246594
    Sofiya, Sofia 1431, Bulgaria
  • Medical center Cordis /ID# 253310
    Pleven, 5800, Bulgaria
  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 246395
    Sofia, 1407, Bulgaria
  • Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 247027
    Sofia, 1407, Bulgaria
  • Medical Center Euroderma /ID# 246736
    Sofia, 1606, Bulgaria
  • Medical center EuroHealth /ID# 246305
    Sofia, 1606, Bulgaria
  • Dermatology Research Institute - Blackfoot Trail /ID# 246703
    Calgary, Alberta T2J 7E1, Canada
  • Beacon Dermatology Inc /ID# 246705
    Calgary, Alberta T3A 2N1, Canada
  • Rejuvenation Dermatology - Edmonton Downtown /ID# 256790
    Edmonton, Alberta T5J 3S9, Canada
  • Alberta DermaSurgery Centre /ID# 247286
    Edmonton, Alberta T6G 1C3, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 246700
    Surrey, British Columbia V3R 6A7, Canada
  • Lynde Institute for Dermatology /ID# 246699
    Markham, Ontario L3P 1X2, Canada
  • SKiN Centre for Dermatology /ID# 246702
    Peterborough, Ontario K9J 5K2, Canada
  • Private Practice - Dr. Kim Papp Clinical Research /ID# 246698
    Waterloo, Ontario N2J 1C4, Canada
  • Beijing Friendship Hospital /ID# 247719
    Beijing, Beijing Municipality 100032, China
  • Peking University Third Hospital /ID# 247842
    Beijing, Beijing Municipality 100191, China
  • Dermatology Hospital of Southern Medical University /ID# 247951
    Guangzhou, Guangdong 510091, China
  • The First Hospital of China Medical University /ID# 247686
    Shenyang, Liaoning 110001, China
  • Huashan Hospital, Fudan University /ID# 247680
    Shanghai, Shanghai Municipality 200040, China
  • Dermatologische Gemeinschaftspraxis Mahlow /ID# 245629
    Blankenfelde-Mahlow, Brandenburg 15831, Germany
  • Klinikum Darmstadt /ID# 247028
    Darmstadt, Hesse 64283, Germany
  • Universitaetsklinikum Frankfurt /ID# 245627
    Frankfurt am Main, Hesse 60590, Germany
  • Fachklinik Bad Bentheim /ID# 245634
    Bad Bentheim, Lower Saxony 48455, Germany
  • Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 245636
    Bramsche, Lower Saxony 49565, Germany
  • Universitaetsklinikum Muenster /ID# 245623
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitaetsklinikum Carl Gustav Carus Dresden /ID# 248413
    Dresden, Saxony 01307, Germany
  • Elbe Klinikum Buxtehude /ID# 245626
    Buxtehude, 21614, Germany
  • Derma Study Center Friedrichshafen GmbH /ID# 245640
    Friedrichshafen, 88045, Germany
  • Universitaetsklinikum Halle (Saale) /ID# 245637
    Halle, 06120, Germany
  • Dermatologikum Hamburg /ID# 245635
    Hamburg, 20354, Germany
  • Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 245628
    Mainz, 55128, Germany
  • Gyongyosi Bugat Pal Korhaz /ID# 246422
    Gyöngyös, Heves County 3200, Hungary
  • Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 246428
    Kaposvár, Somogy County 7400, Hungary
  • Clinexpert Kft /ID# 246427
    Budapest, 1033, Hungary
  • DERMA-B Egeszsegugyi es Szolgaltato - Debrecen - Gyepusor Utca /ID# 246426
    Debrecen, 4031, Hungary
  • IRCCS Istituto Clinico Humanitas /ID# 246630
    Rozzano, Lombardy 20089, Italy
  • Duplicate_Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 254355
    Ancona, 60126, Italy
  • Duplicate_ASST Spedali civili di Brescia /ID# 246631
    Brescia, 25123, Italy
  • Universita degli Studi Gabriele dAnnunzio /ID# 246629
    Chieti, 66100, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 246634
    Milan, 20122, Italy
  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 246632
    Perugia, 06156, Italy
  • Miyata Dermatology Clinic /ID# 255491
    Matsudo-Shi, Chiba 271-0092, Japan
  • Fukuoka University Hospital /ID# 255182
    Fukuoka, Fukuoka 814-0180, Japan
  • Takagi Dermatological Clinic /ID# 255181
    Obihiro-shi, Hokkaido 080-0013, Japan
  • Nomura Dermatology Clinic /ID# 255534
    Yokohama, Kanagawa 221-0825, Japan
  • Tohoku University Hospital /ID# 255183
    Sendai, Miyagi 9808574, Japan
  • Maruyama Dermatology Clinic /ID# 255441
    Koto-ku, Tokyo 136-0074, Japan
  • Amphia Ziekenhuis /ID# 246397
    Breda, North Brabant 4818 CK, Netherlands
  • Amsterdam UMC, locatie AMC /ID# 245673
    Amsterdam, North Holland 1105 AZ, Netherlands
  • Greenlane Clinical Centre /ID# 246556
    Epsom, Auckland 1051, New Zealand
  • Clinical Trials New Zealand /ID# 246557
    Hamilton, Waikato Region 3204, New Zealand
  • Aotearoa Clinical Trials /ID# 246559
    Auckland, 1640, New Zealand
  • Duplicate_Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej Alergologia Plus /ID# 253508
    Poznan, Greater Poland Voivodeship 60-693, Poland
  • Specjalistyczna Przychodnia Lekarska Alergo-Med sp. z o.o. /ID# 253846
    Poznan, Greater Poland Voivodeship 61-578, Poland
  • Oftalmika sp. z o.o. /ID# 253429
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-631, Poland
  • MICS Centrum Medyczne Torun /ID# 245749
    Torun, Kuyavian-Pomeranian Voivodeship 87-100, Poland
  • Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. /ID# 245836
    Krakow, Lesser Poland Voivodeship 31-011, Poland
  • CenterMed Krakow Sp. z o.o. /ID# 253940
    Krakow, Lesser Poland Voivodeship 31-530, Poland
  • Klinika Ambroziak Sp. z o.o. /ID# 245748
    Warsaw, Masovian Voivodeship 02-953, Poland
  • Royalderm Agnieszka Nawrocka /ID# 245746
    Warsaw, Masovian Voivodeship 02-962, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 245741
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Centrum Medyczne Pratia Gdynia /ID# 245835
    Gdynia, Pomeranian Voivodeship 81-338, Poland
  • Silmedic Sp. z o.o. /ID# 253863
    Katowice, Silesian Voivodeship 40-282, Poland
  • Dermed Centrum Medyczne Sp. z o.o /ID# 246329
    Lodz, Łódź Voivodeship 90-265, Poland
  • Santa Sp. z o.o. Santa Familia Centrum Badan, Profilaktyki i Leczenia /ID# 253872
    Lodz, Łódź Voivodeship 90-302, Poland
  • Centro Hospitalar de Lisboa Central /ID# 246247
    Lisbon, 1169-050, Portugal
  • Hospital CUF Descobertas /ID# 245702
    Lisbon, 1998-018, Portugal
  • Centro Hospitalar Universitario do Porto, EPE - Hospital Santo Antonio /ID# 245701
    Porto, 4099-001, Portugal
  • Centro Hospitalar Universitario de Sao Joao, EPE /ID# 245704
    Porto, 4200-319, Portugal
  • Poliklinika Bezrucova (Cliniq s.r.o.) /ID# 247515
    Bratislava, 811 09, Slovakia
  • BeneDerma s.r.o. /ID# 247513
    Bratislava, 841 04, Slovakia
  • Univerzitna nemocnica Martin /ID# 246948
    Martin, Žilina Region 036 01, Slovakia
  • Korea University Ansan Hospital /ID# 245653
    Ansan-si, Gyeonggido 15355, South Korea
  • Soon Chun Hyang University Hospital Bucheon /ID# 245654
    Bucheon-si, Gyeonggido 14584, South Korea
  • Ajou University Hospital /ID# 245652
    Suwon, Gyeonggido 16499, South Korea
  • Chungang University Hospital /ID# 245655
    Dongjak-gu, Seoul Teugbyeolsi 06973, South Korea
  • Seoul National University Hospital /ID# 245651
    Seoul, Seoul Teugbyeolsi 03080, South Korea
  • Konkuk University Medical Center /ID# 245657
    Seoul, Seoul Teugbyeolsi 05030, South Korea
  • Hospital Universitario Germans Trias i Pujol /ID# 246320
    Badalona, Barcelona 08916, Spain
  • Hospital Universitari de Bellvitge /ID# 246326
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 253820
    Majadahonda, Madrid 28222, Spain
  • Hospital General Universitario de Alicante Doctor Balmis /ID# 246270
    Alicante, 03010, Spain
  • Hospital Universitario Infanta Leonor /ID# 246272
    Madrid, 28031, Spain
  • Hospital Universitario Ramon y Cajal /ID# 246273
    Madrid, 28034, Spain
  • Complejo Hospitalario Universitario de Pontevedra /ID# 246323
    Pontevedra, 36071, Spain
  • Hospital Universitario Virgen del Rocio /ID# 253822
    Seville, 41013, Spain
  • Kaohsiung Chang Gung Memorial Hospital /ID# 245710
    Kaohsiung City, Kaohsiung 833, Taiwan
  • National Taiwan University Hospital /ID# 245711
    Taipei City, Taipei 100, Taiwan
  • Chung Shan Medical University Hospital /ID# 245707
    Taichung, 40201, Taiwan
  • Mackay Memorial Hospital /ID# 245713
    Taipei, 104, Taiwan

Showing the first 100 of 106 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jul 2024, 13 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2022
First posted
Aug 19, 2022
StartActual
May 29, 2023
Primary completionActual
Jul 11, 2024
CompletionActual
Aug 15, 2024
Results first posted
Jul 29, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05507580
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
May 29, 2023
Primary completion
Jul 11, 2024
Completion
Aug 15, 2024
Results posted
Jul 29, 2025
Last update
Jul 29, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion